ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration for Phase I clinical trial in China on March 29, 2023.
ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration for Phase I clinical trial in China on March 29, 2023.